Last updated on October 2017

Single and Multiple Dose Study of BIIB067 in Adults With Amyotrophic Lateral Sclerosis (ALS)


Brief description of study

The primary objective of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of BIIB067 in adults with ALS. The secondary objective is to evaluate the effects of BIIB067 on levels of superoxide dismutase 1 (SOD1) protein in the cerebrospinal fluid (CSF).

Clinical Study Identifier: NCT02623699

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Biogen

Barrow Neurological Institute
Phoenix, AZ United States
  Connect »

Biogen

University of California San Diego Medical Center
La Jolla, CA United States
  Connect »

Biogen

California Pacific Medical Center
San Francisco, CA United States
  Connect »

Biogen

Compass Research, LLC
Orlando, FL United States
  Connect »

Biogen

The Emory Clinic
Atlanta, GA United States
  Connect »

Biogen

Johns Hopkins Hospital
Baltimore, MD United States
  Connect »

Biogen

Massachusetts General Hospital, MA
Boston, MA United States
  Connect »

Biogen

Washington University School of Medicine
Saint Louis, MO United States
  Connect »

Biogen

Volunteer Research Group, LLC
Knoxville, TN United States
  Connect »

Biogen

UZ Leuven
Leuven, Belgium
  Connect »

Biogen

Sunnybrook Health Sciences Centre
Toronto, ON Canada
  Connect »

Biogen

Montreal Neurological Institute Clinical Research Unit
Montreal, QC Canada
  Connect »

Biogen

Groupe Hospitalier Pitie-Salpetriere
Paris, France
  Connect »

Biogen

Universitaetsklinikum Ulm
Ulm, Germany
  Connect »

Biogen

Universit degli Studi di Torino
Torino, Italy
  Connect »

Biogen

Norrlands universitetssjukhus
Umea, Sweden
  Connect »

Biogen

Sheffield Institute for Translational Neuroscience
Sheffield, United Kingdom
  Connect »